CER 209

Drug Profile

CER 209

Alternative Names: CER-209

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerenis Therapeutics
  • Class Antihyperlipidaemics; Vascular disorder therapies
  • Mechanism of Action P2RY13 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Non-alcoholic steatohepatitis

Most Recent Events

  • 15 Dec 2016 US FDA approves IND application for Non-alcoholic fatty liver disease and Non-alcoholic steato hepatitis and Non-alcoholic fatty liver disease
  • 15 Dec 2016 Cerenis Therapeutics plans a phase I trial for Non-alcoholic fatty liver disease and Non-alcoholic steato-hepatitis
  • 25 Feb 2016 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis released by Cerenis Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top